It’s time for health insurers and health-care providers to stop lagging behind medical innovation, the head of the Department of Health and Human Services is telling the industry.
“Personalized medicine has come to life, and cell therapies are receiving FDA approval,” Alex Azar, a former drug industry chief, told the Federation of American Hospitals earlier this week. “But innovation in payment and delivery systems is simply not proceeding at the same pace,” he said.
Azar, who is speaking to America’s Health Insurance Plans March 8, noted that the shift away from fee-for-service payments to a value-based system has been going on for more than a decade, and “is still far from reaching its potential.”
“Medical science is rapidly moving towards precision treatments at the level of an individual’s genes,” Mark Fendrick, director of the University of Michigan’s Center for Value-Based Insurance Design, told me.
“Yet our ability to provide these amazing innovations is in the Stone Age. I call it Star Wars science and Flintstones delivery.”
Under Azar, the HHS is moving to push the industry forward. On March 6, Centers for Medicare & Medicaid Services Administrator Seema Verma announced at a gathering of health information technology executives in Las Vegas the MyHealthEData initiative as well as Medicare’s Blue Button 2.0 program to give patients access to their health data and share it with providers.
Verma called on health insurers to follow CMS’s lead and give patients access to their claims data in a digital format.
Azar also broached the topic of Medicare demonstration projects. The Trump administration scrapped two Obama administration demonstrations bundling payments for some procedures. But at the FAH conference, Azar said HHS wants to look at “bold measures that will fundamentally reorient how Medicare and Medicaid pay for care and create a true competitive playing field where value is rewarded handsomely.”
Read my full article here.
Stay on top of new developments in health law and regulation, and learn more, by signing up for a free trial to Bloomberg Law.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)